Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
European Journal of Immunology|June 12, 2008
IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivoIvo Sonderegger, Jan Kisielow, Reto Meier, et al.
The Journal of Experimental Medicine|September 10, 2008
GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survivalIvo Sonderegger, Giandomenica Iezzi, Reinhard Maier, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2009
CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cellsGiandomenica Iezzi, Ivo Sonderegger, Franziska Ampenberger, et al.
Blood|November 2, 2006
IL-21 receptor signaling is integral to the development of Th2 effector responses in vivoAnja Fröhlich, Benjamin J Marsland, Ivo Sonderegger, et al.
Vaccine|March 2, 2010
Combined vaccination against IL-5 and eotaxin blocks eosinophilia in miceYu Zou, Ivo Sonderegger, Gerd Lipowsky, et al.
Annals of the Rheumatic Diseases|March 9, 2018
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence studyStanley B Cohen, Alberto Alonso-Ruiz, Piotr A Klimiuk, et al.
Journal of Autoimmunity|March 6, 2007
Molecular mapping of autoimmune B cell responses in experimental myocarditisPhilippe Krebs, Michael O Kurrer, Marcel Kremer, et al.
European Journal of Immunology|October 14, 2006
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditisIvo Sonderegger, Till A Röhn, Michael O Kurrer, et al.
Expert Opinion on Investigational Drugs|November 5, 2016
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjectsChristopher Wynne, Mario Altendorfer, Ivo Sonderegger, et al.
Rheumatology and Therapy|July 1, 2018
Similar Pharmacokinetics of the Adalimumab (Humira®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group TrialsSteven Ramael, Benjamin Van Hoorick, Renger Tiessen, et al.
Pageof 3